Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells

Molecular Biology Reports

Volumn 41, Issue 1, 2014, Pages 19-24

  Hu, Pinghua ^a   Huang, Qin ^a   Li, Zhihua ^a   Wu, Xiaobo ^a   Ouyang, Qianwen ^a   Chen, Jun ^a   Cao, Yali ^a  

^a Jiangxi Breast Center Third Hospital of Nanchang   (China)

Author keywords

Breast cancer; Cell cycle paclitaxel; MAP3K1; siRNA

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PACLITAXEL; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN MCF 12F; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CDC25 PHOSPHATASES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN B1; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAMMARY GLANDS, HUMAN; MAP KINASE KINASE KINASE 1; MCF-7 CELLS; PACLITAXEL; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84891945881     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2811-0     Document Type: Article

References (28)

1. Boghaert E, Gleghorn JP, Lee K, Gjorevski N, Radisky DC, Nelson CM (2012) Host epithelial geometry regulates breast cancer cell invasiveness. Proc Natl Acad Sci USA 109(48):19632-19637
2. Hartmann JT, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm MM, Heeger S, Bokemeyer C (2012) A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Investig New Drugs 31(3):661-668
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550
4. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd et al (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4):362-371
5. Parmar MKLJ, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106
6. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simao AN, Cecchini AL, Cecchini R (2012) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133(1):89-97
7. Ready NE, Rathore R, Johnson TT, Nadeem A, Chougule P, Ruhl C, Radie-Keane K, Theall K, Wanebo HJ, Marcello J et al (2012) Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 35(1):6-12
8. Kato H, Yanagisawa N, Sasaki S, Hosoda T, Suganuma A, Imamura A, Ajisawa A (2012) Refractory AIDS-associated Kaposi's sarcoma treated successfully with paclitaxel: a case report. Kansenshogaku Zasshi 86(3):287-290
9. Geh E, Meng Q, Mongan M, Wang J, Takatori A, Zheng Y, Puga A, Lang RA, Xia Y (2011) Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) integrates developmental signals for eyelid closure. Proc Natl Acad Sci USA 108(42):17349-17354
10. Geh E, Jin C, Xia Y (2010) Map3k1. UCSD-Nature Molecule Pages, UCSD-Nature Signaling Gateway (www signaling-gateway org)
11. Xu CS, Zheng JY, Zhang HL, Zhao HD, Zhang J, Wu GQ, Wu L, Wang Q, Wang WZ (2012) MSP58 knockdown inhibits the proliferation of esophageal squamous cell carcinoma in vitro and in vivo. Asian Pac J Cancer Prev 13(7):3233-3238
12. Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G (2003) Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 303(4):1169-1178
13. Borkhardt A (2002) Blocking oncogenes in malignant cells by RNA interference-new hope for a highly specific cancer treatment? Cancer Cell 2(3):167-168
14. Iorns E, Lord CJ, Turner N, Ashworth A (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6(7):556-568
15. Slattery ML, Lundgreen A, Wolff RK (2012) MAP kinase genes and colon and rectal cancer. Carcinogenesis 33(12):2398-2408
16. Klinge CM (2005) Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 280:7460-7468
17. Sue Ng S, Mahmoudi T, Li VS, Hatzis P, Boersema PJ, Mohammed S, Heck AJ, Clevers H (2010) MAP3K1 functionally interacts with Axin1 in the canonical Wnt signalling pathway. Biol Chem 391(2-3):171-180
18. Pearlman A, Loke J, Le Caignec C, White S, Chin L, Friedman A, Warr N, Willan J, Brauer D, Farmer C et al (2010) Mutations in MAP3K1 cause 46, XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. Am J Hum Genet 87(6):898-904
19. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9(7):1829-1838
20. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW (1994) A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 18(2):79-85
21. Katano M (2005) Hedgehog signaling pathway as a therapeutic target in breast cancer. Cancer Lett 227:99-104
22. MakotoKubo MN, Tasaki Akira, Yamanaka Naoki, Nakashima Hiroshi, Nomura Masatoshi, Kuroki Syoji, Katano Mitsuo (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64:6071-6074
23. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087-1093
24. Rebbeck TR, DeMichele A, Tran TV, Panossian S, Bunin GR, Troxel AB, Strom BL (2009) Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis 30(2):269-274
25. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Wijers-Koster PM, Blom JC, Pooley KA, Klijn JG et al (2007) Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 9(6):R78
26. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI et al (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4(4):e1000054
27. Mongan M, Wang J, Liu H, Fan Y, Jin C, Kao WY, Xia Y (2011) Loss of MAP3K1 enhances proliferation and apoptosis during retinal development. Development 138(18):4001-4012
28. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N (2000) MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79(3):355-369